Click Here for 5% Off Your First Aladdin Purchase!

Clazakizumab (anti-IL-6) - Primary antibody, specific to IL6, >95% (SDS-PAGE&SEC), high purity, Human IgG1, INHIBITOR of Interleukin-6 inhibitor

  • Azide Free
  • Carrier Free
  • ExactAb™
  • Low Endotoxin
  • Recombinant
  • Validated
  • ≥95%(SDS-PAGE&SEC)
  • Lot by Lot
Features and benefits
  • Short Overview:

    Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

  • Species reactivity(Reacts with): Cynomolgus monkey,Human,Mouse
  • Isotype: Human IgG1
    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Item Number
Ab175494
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175494-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$109.90
Ab175494-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$519.90
Ab175494-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,399.90
Ab175494-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,239.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series
Accession#:P05231 Gene ID:3569 IL6

Basic Description

Product NameClazakizumab (anti-IL-6) - Primary antibody, specific to IL6, >95% (SDS-PAGE&SEC), high purity, Human IgG1
SynonymsALD-518;ALD518;BMS-945429
Specifications & PurityExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Biochemical and Physiological Mechanisms Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It indu
SpecificityIL6
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeINHIBITOR
Mechanism of actionINHIBITOR of Interleukin-6 inhibitor
Product Description

Clazakizumab (anti-IL-6) is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab (anti-IL-6) may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab (anti-IL-6) can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection.


Product Properties

IsotypeHuman IgG1
Light Chain Typekappa
SDS-PAGE145.24 kDa
Purification MethodProtein A purified
Purity>95% (SDS-PAGE&SEC)
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS1236278-28-6

Associated Targets

IL6 Tclin Interleukin-6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR.  (2011)  A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer..  Expert Opin Biol Ther,  11  (12): (1663-8).  [PMID:21995322]
2. Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S.  (2016)  The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis..  Arthritis Rheumatol,  68  (9): (2163-73).  [PMID:27059799]
3. Ma JD, Heavey SF, Revta C, Roeland EJ.  (2014)  Novel investigational biologics for the treatment of cancer cachexia..  Expert Opin Biol Ther,  14  (8): (1113-20).  [PMID:24707881]
4. FitzGerald O.  (2016)  Spondyloarthropathies: IL-6 blockade in psoriatic arthritis - a new therapeutic option?.  Nat Rev Rheumatol,  12  (6): (318-9).  [PMID:27215204]
5. Weinblatt ME, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, Xing J, Zilberstein M, Banerjee S, Emery P.  (2015)  The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study..  Arthritis Rheumatol,  67  (10): (2591-600).  [PMID:26138593]

Solution Calculators